Therapeutic regimens for brucellosis
Phase 4
- Conditions
- Brucellosis.Brucellosis
- Registration Number
- IRCT201101245681N1
- Lead Sponsor
- Vice-Chancellor of Research and Technology,Hamedan University of Medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 191
Inclusion Criteria
clinical presentations compatible with brucellosis in the presence of significant titers of specific antibodies (standard tube agglutination = 1/160, coomb’s test = 1/160, 2-mercaptoetanol = 1-80, or Brucella IgG-ELISA > 12) and/or a positive blood culture for Brucella
Exclusion criteria: age under 17 years, brucella endocarditis, neurobrucellosis, pregnancy, renal failure, hepatic failure, a history of treatment for brucellosis in the last six months
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Therapeutic failure. Timepoint: 6 weeks. Method of measurement: Physical examination.;Relapse. Timepoint: 6 months. Method of measurement: physical examination and 2-ME testing (2-ME>or=1/80).
- Secondary Outcome Measures
Name Time Method Adverse reaction. Timepoint: 2, 4, 6 weeks. Method of measurement: observation.